Tretazicar

DB04253InvestigationalSmall molecule

Tretazicar is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).

Chemical structure of Tretazicar
Mechanism
Curator reviewed
Formula / weight
C9H8N4O5 · 252.1836 g/mol (avg)
Code names
CB-1954 · NSC-115829

Resolves to

Compound
UNII7865D5D01MCAS21919-05-1ChEMBLCHEMBL23330PubChem89105
Structure
InChIKeyWOCXQMCIOTUMJV-UHFFFAOYSA-NSMILESNC(=O)C1=CC(N2CC2)=C(C=C1[N+]([O-])=O)[N+]([O-])=O
Targets
P16083NQO2P38489nfsB

What you can answer from here — as of September 16, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tretazicar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In